Crossject
Created in 2001
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,163 5,076Activities
Technologies
Entity types
Location
6 Rue Pauline Kergomard, 21000 Dijon, France
Dijon
France
Employees
Scale: 51-200
Estimated: 95
Engaged corporates
19
7 1Added in Motherbase
3 years, 1 month ago
deeptech Value proposition
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Injection sans aiguile and Traitements d'urgenceOriginal language
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Crossject | Needle free injection | ZENEO®
Crossject developed ZENEO®, a world-leading needle-free injection platform, designed to improve patients’ safety and comfort and to enable a better observance of treatments. Needleless free injection of medicinal solution.
https://www.crossject.com/en
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 La French Tech Bourgogne-Franche-Comté French Tech, Non-profit Organizations | La French Tech Bourgogne-Franche-Comté French Tech, Non-profit Organizations | Other 8 Apr 2024 | | |
 Dijon métropole Government Administration, French metropolis | Dijon métropole Government Administration, French metropolis | Other 5 Jun 2023 | | |
 PMT Public business cluster, French Cluster, Civic and Social Organizations | PMT Public business cluster, French Cluster, Civic and Social Organizations | Other 15 Jul 2020 28 Aug 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 6 Mar 2017 16 Jul 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 17 Oct 2023 | | |
 Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Not capitalistic Partnership Event 17 Nov 2023 | | |
 La French Tech Est Startup accelerator & VC, French Tech, Business Consulting and Services | La French Tech Est Startup accelerator & VC, French Tech, Business Consulting and Services | Other 3 Oct 2017 | | |
 Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Not capitalistic Not partnership Event 17 Oct 2023 | | |
 CIC Bank, Banking | CIC Bank, Banking | Not capitalistic Not partnership Event 16 Apr 2021 | | |